mRNA-1283.815

mRNA-1283.815 is a next-generation, refrigerator-stable mRNA vaccine candidate developed by Moderna for the prevention of COVID-19. Unlike the first-generation mRNA-1273 vaccine, which encodes the full-length spike protein of SARS-CoV-2, mRNA-1283 is designed to encode only the specific portions of the spike protein—the receptor-binding domain (RBD) and the N-terminal domain (NTD)—that are most critical for neutralizing the virus. The ".815" designation specifies that this particular formulation is adapted to target the XBB.1.5 Omicron subvariant. A key advantage of the mRNA-1283 program is its improved thermal stability, allowing for storage at standard refrigerator temperatures (2-8°C), which simplifies distribution and storage logistics compared to earlier mRNA vaccines that required ultra-cold storage.

Other names

mRNA-1283 (XBB.1.5 variant)XBB.1.5-adapted mRNA-1283